与遗传性血管 (HAE) 按需治疗相关的决策的复杂性引起了攻击
Stephen D Betschel1, Teresa Caballero2, Douglas H Jones3
1Clinical Immunology and Allergy, Department of Medicine, University of Toronto, Toronto, ON, Canada. Stephen.Betschel@unityhealth.to.
概括
许多遗传性血管患者因与治疗相关的负担而推迟按需治疗. 这种延迟往往导致更严重的攻击和更长的恢复时间遗传性血管 (HAE) 患者.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 遗传性血管 (HAE) 导致严重的发作.
- 建议早期按需治疗,但患者往往会推迟治疗.
- 患者的行为显著影响HAE管理.
研究的目的:
- 调查患者在HAE按需治疗决策中的行为.
- 确定影响治疗延迟的关键因素.
- 了解患者对HAE攻击管理的看法.
主要方法:
- 在线调查通过美国遗传性血管水协会 (HAEA) 分发给HAE患者.
- 在2022年9月6日至10月19日期间进行的调查.
- 107名HAE患者 (80%为女性,98%为成年人) 完成了调查.
主要成果:
- 63.6%的患者在远离家园时没有进行按需治疗.
- 86%的人报告推迟按需治疗,理由包括"攻击不够严重"和"成本".
- 治疗延迟导致发作严重程度增加 (75%) 和恢复时间延长 (80%).
结论:
- 在HAE中,按需治疗的决定是复杂的.
- 当前亲肠道治疗的负担导致治疗延迟.
- 延迟治疗加剧了HAE攻击的严重程度,并延长了恢复时间.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
663
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
663
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
150
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
150
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
Heart Failure Drugs: Diuretics
356
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
356
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
483
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
483
Local Anesthetics: Pharmacokinetics
754
The potency and duration of action of local anesthetics (LAs) are determined by their pharmacokinetics. Pharmacokinetics describes how LAs are absorbed, distributed, metabolized, and eliminated from the body. When administered to the vascular tissues, LAs are quickly absorbed and enter the systemic circulation, reducing their localized effects. Adding vasoconstrictors such as epinephrine to LAs reduces their absorption into the systemic circulation, making them clinically effective. The...
754


